<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">IIDA, TETSUHIRO</style></author><author><style face="normal" font="default" size="100%">NOZAWA, HIROAKI</style></author><author><style face="normal" font="default" size="100%">SONODA, HIROFUMI</style></author><author><style face="normal" font="default" size="100%">TOYAMA, KAZUHIRO</style></author><author><style face="normal" font="default" size="100%">KAWAI, KAZUSHIGE</style></author><author><style face="normal" font="default" size="100%">HATA, KEISUKE</style></author><author><style face="normal" font="default" size="100%">TANAKA, TOSHIAKI</style></author><author><style face="normal" font="default" size="100%">NISHIKAWA, TAKESHI</style></author><author><style face="normal" font="default" size="100%">SASAKI, KAZUHITO</style></author><author><style face="normal" font="default" size="100%">SHUNO, YASUTAKA</style></author><author><style face="normal" font="default" size="100%">KANEKO, MANABU</style></author><author><style face="normal" font="default" size="100%">MURONO, KOJI</style></author><author><style face="normal" font="default" size="100%">EMOTO, SHIGENOBU</style></author><author><style face="normal" font="default" size="100%">ISHII, HIROAKI</style></author><author><style face="normal" font="default" size="100%">KUROKAWA, MINEO</style></author><author><style face="normal" font="default" size="100%">ISHIHARA, SOICHIRO</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Upfront Surgery for Small Intestinal Non-Hodgkin's Lymphoma</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-04-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">2373-2377</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.14206</style></doi><volume><style face="normal" font="default" size="100%">40</style></volume><issue><style face="normal" font="default" size="100%">4</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: The clinical significance of surgery for secondary small intestinal non-Hodgkin's lymphomas (NHL) remains unknown. This study aimed to investigate the efficacy of resection for both primary and secondary small intestinal NHL. Patients and Methods: Twenty patients with small intestinal lymphoma who underwent surgical resection at our Institute between 2009 and 2017 were retrospectively evaluated. The clinicopathological and surgery-related factors were reviewed. We also analyzed their surgical outcomes such as postoperative complications, perforation rate, and overall survival (OS). Results: In total, 13 (65%) and 7 (35%) patients had primary and secondary lymphomas, respectively. A total of 70% of patients were diagnosed with aggressive-type lymphomas. A total of 15 (75%) patients had Lugano system stage IV. Only one (5%) patient experienced postoperative grade II deep vein thrombosis and pulmonary embolism. The 3-year OS rate after surgery was 59.6%. Conclusion: Surgical resection prior to chemotherapy is a feasible and safe therapeutic strategy for small intestinal NHL.</style></abstract></record></records></xml>